Table IV.
Clinicopathological implications of TILs for patients with primary stage IV disease.
| No. | Age | ER/HER2 | Ki-67 (%) | Metastatic site | TILs | Outcome | f/u (months) | Other information |
|---|---|---|---|---|---|---|---|---|
| 1 | 66 | +/− | 20 | Bone, lung, LN | Low | PD | 16 | |
| 2 | 67 | +/− (rt.) | 2 | Lung | Low | SD | 19 | Bilateral |
| +/− (lt.) | 2 | Lung | Low | SD | 19 | |||
| 3 | 65 | +/− | 20 | Lung | Low | SD | 50 | |
| 4 | 85 | +/− | 50 | Lung | Low | PR | 11 | |
| 5 | 59 | +/− | 7.5 | Bone, lung, LN | Intermediate | SD | 15 | |
| 6 | 68 | +/− | 20 | Bone | Low | cCR | 29 | |
| 7 | 59 | +/− | 5 | Bone, liver, LN | Low | Deceased | 10 | ILC |
| 8 | 89 | +/− | 10 | Bone, lung | Low | Deceased | 10 | ILC |
| 9 | 80 | +/− | 10 | Bone | Low | PD | 57 | |
| 10 | 56 | +/− | 4 | Contralateral breast, bone, pleura, LN, peritoneum | Intermediate | Deceased | 7 | ILC |
| 11 | 58 | +/− | / | Bone, pleura, lung | Low | Deceased | 43 | IMPC |
| 12 | 61 | +/− | 40 | Bone, liver | Low | Deceased | 4 | |
| 13 | 61 | +/− | 1.5 | Lung | Low | cCR | 69 | |
| 14 | 66 | +/− | / | Bone, lung, liver, LN | Low | Deceased | 66 | |
| 15 | 54 | +/− | / | Bone, pleura, pericardiac membrane | Intermediate | Deceased | 62 | |
| 16 | 44 | +/− (rt.) | 2 | Bone | Intermediate | PD | 14 | Bilateral |
| 44 | +/+ (lt.) | 3 | Bone | Intermediate | PD | 14 | ||
| 17 | 64 | +/+ | 10 | Bone, liver | Low | PR | 3 | |
| 18 | 36 | +/+ | 30 | Bone, lung | Low | PR | 19 | |
| 19 | 62 | −/+ | 50 | Lung, liver | Intermediate | SD | 48 | |
| 20 | 56 | −/+ | 90 | Contralateral LN | Low | cCR | 14 | Fig. 3B |
| 21 | 32 | −/+ | 50 | Lung, LN | High | cCR | 38 | Fig. 3A |
| 22 | 57 | −/+ | 40 | Bone, pleura, LN, contralateral breast, local | Intermediate | PD | 37 | |
| 23 | 75 | −/− | 5 | Bone, lung, liver, muscle | Low | Deceased | 4 | |
| 24 | 87 | −/− | 7.5 | Bone | Low | SD | 2 | |
| 25 | 60 | −/− | / | Pleura, local | Low | Deceased | 67 | |
| 26 | 85 | −/− | / | Lung, peritoneum, LN | Low | SD | 1 |
TILs, tumor infiltrating lymphocytes; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; rt., right; lt., left; LN, lymph nodes; cCR, clinical complete response; PR, partial response; SD, stable disease; PD, progressive disease; BC, breast cancer; f/u, follow up; ILC, invasive lobular carcinoma; IMPC, invasive micropapillary carcinoma.